Alpha Biologics is a contract process development and GMP bio-manufacturing company.
It has process development laboratories located in the biotech cluster of Cambridge, UK and a GMP mammalian cell clinical production facility located in the Penang Science Park, Malaysia, with 30 employees.
Alpha Biologics provides its clients with supplies of mammalian cell proteins, such as monoclonal antibodies or recombinant proteins, or other cell-derived products.
Over the next few months, the plant will undergo due process to obtain its certification under the Pharmaceutical Inspection Cooperation Scheme (PIC/s), which is a global harmonization scheme for Good Manufacturing Practices (GMP) with 39 member countries and agencies, including the US FDA.
EMEA accreditation will follow thereafter.
Viropro president and CEO Rajiv Datar said with this acquisition, Viropro has taken the first step towards creating a global biotech contract services business, and towards achieving the goal of offering an integrated Contract Development and GMP Manufacturing Services platform to clients in the Biopharmaceutical industry.
Alpha Biologics and SpringHill Management chairman Kim Tan said the transaction allows them to participate in the entire biotech Contract Development and Manufacturing services offering, and thus provides increased leverage to their Penang facility.